Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter

Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter (Form 6-K) (Aurora Cannabis Inc)

) Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $244.4 million, representing 39% YoY growth Delivers Record Adjusted EBITDA1 of $49.7 million, representing 261% YoY growth Generates Annual

Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter

/PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today...

GMS Reports Fourth Quarter and Fiscal Year 2025 Results

TUCKER, Ga.--(BUSINESS WIRE)--Jun 18, 2025-

Aurora reports increased international sales, but significant loss in Q4 2025

Aurora Cannabis reported $90.5 million in net revenue for the three months ended March 31, 2025 (Q4 2025), $27.6 million in gross profit, and a... The post Aurora reports increased international sales, but significant loss in Q4 2025 appeared first on StratCann.

Aurora Cannabis Inc. (ACB) Files Full Year Results and Announces Fiscal 2025 Fourth Quarter

Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. “We are pleased to report an exceptional year to our shareholders, highlighted by record annual global medic…